Baxter International (NYSE:BAX – Get Free Report) and LENSAR (NASDAQ:LNSR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.
Institutional & Insider Ownership
90.2% of Baxter International shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 0.2% of Baxter International shares are owned by insiders. Comparatively, 65.8% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Baxter International has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Baxter International and LENSAR, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Baxter International | 3 | 10 | 1 | 0 | 1.86 |
| LENSAR | 1 | 0 | 2 | 0 | 2.33 |
Baxter International presently has a consensus price target of $23.27, indicating a potential downside of 8.83%. LENSAR has a consensus price target of $11.00, indicating a potential upside of 107.94%. Given LENSAR’s stronger consensus rating and higher probable upside, analysts plainly believe LENSAR is more favorable than Baxter International.
Profitability
This table compares Baxter International and LENSAR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Baxter International | -6.23% | 16.23% | 5.08% |
| LENSAR | 56.07% | 1,254.25% | 49.13% |
Earnings & Valuation
This table compares Baxter International and LENSAR”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Baxter International | $11.61 billion | 1.14 | -$957.00 million | ($1.41) | -18.10 |
| LENSAR | $60.08 million | 1.08 | -$34.28 million | ($0.40) | -13.22 |
LENSAR has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.
Summary
LENSAR beats Baxter International on 11 of the 14 factors compared between the two stocks.
About Baxter International
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
About LENSAR
LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens. The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
